

# Gardner

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	14.61	16	110	Male	9.49	7	74
Female	5.92	5	85	Female	7.00	3	NC*
Total	20.53	21	102	Total	16.49	10	61
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	4.21	3	NC*	Male	2.78	2	NC*
Female	3.32	2	NC*	Female	2.52	3	NC*
Total	7.53	5	66	Total	5.30	5	94
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.67	1	NC*	Male	11.60	14	121
Female	83.19	66	79	Female	10.63	13	122
Total	83.86	67	80	Total	22.23	27	121
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	4.55	6	132	Male	8.61	7	81
				Female	4.30	7	163
				Total	12.91	14	108
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	36.10	47	130	Female	9.67	14	145
Female	37.24	38	102				
Total	73.34	85	116				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	5.02	6	119	Male	6.03	5	83
Female	1.82	0	NC*	Female	6.79	8	118
Total	6.84	6	88	Total	12.82	13	101
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	2.22	0	NC*	Male	87.26	80	92
Female	1.60	0	NC*				
Total	3.82	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	8.23	10	121	Male	6.12	5	82
Female	5.24	4	NC*	Female	4.09	4	NC*
Total	13.47	14	104	Total	10.22	9	88
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	4.64	7	151	Male	3.50	2	NC*
Female	1.15	1	NC*				
Total	5.79	8	138				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	6.76	5	74	Male	1.89	1	NC*
Female	5.41	6	111	Female	4.59	3	NC*
Total	12.18	11	90	Total	6.48	4	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	3.20	3	NC*	Female	15.90	18	113
Female	1.46	2	NC*				
Total	4.66	5	107				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	45.00	37	82	Male	287.80	271	94
Female	36.01	30	83	Female	273.56	256	94
Total	81.01	67	83	Total	561.36	527	94

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Georgetown

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	4.28	6	140	Male	3.21	6	187
Female	1.46	2	NC*	Female	2.35	2	NC*
Total	5.74	8	139	Total	5.56	8	144
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	1.49	1	NC*	Male	0.90	0	NC*
Female	1.10	1	NC*	Female	0.71	0	NC*
Total	2.59	2	NC*	Total	1.60	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.22	0	NC*	Male	3.79	9	238 #+
Female	28.18	24	85	Female	3.02	6	199
Total	28.40	24	85	Total	6.80	15	220 ~+
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	1.67	2	NC*	Male	3.18	1	NC*
				Female	1.33	1	NC*
				Total	4.50	2	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	10.82	9	83	Female	3.29	1	NC*
Female	9.08	10	110				
Total	19.90	19	95				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	1.73	0	NC*	Male	1.91	0	NC*
Female	0.44	0	NC*	Female	1.69	1	NC*
Total	2.17	0	NC*	Total	3.60	1	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.73	0	NC*	Male	28.94	22	76
Female	0.54	0	NC*				
Total	1.27	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	2.87	3	NC*	Male	1.87	1	NC*
Female	1.59	0	NC*	Female	0.98	3	NC*
Total	4.46	3	NC*	Total	2.85	4	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	1.67	0	NC*	Male	1.07	2	NC*
Female	0.39	0	NC*				
Total	2.06	0	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	2.18	2	NC*	Male	0.68	0	NC*

Female	1.57	0	NC*
Total	3.76	2	NC*

#### Liver and Intrahepatic Bile Ducts

Male	1.11	1	NC*
Female	0.38	0	NC*
Total	1.49	1	NC*

#### Lung and Bronchus

Male	14.38	14	97
Female	10.74	13	121
Total	25.12	27	107

Female	1.72	0	NC*
Total	2.40	0	NC*

#### Uteri, Corpus and Uterus, NOS

Female	5.48	4	NC*
--------	------	---	-----

#### All Sites / Types

Male	93.09	83	89
Female	83.28	74	89
Total	176.37	157	89

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Gill

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>			
Male	1.22	2	NC*
Female	0.37	1	NC*
Total	1.58	3	NC*

#### **Brain and Other Central Nervous System**

Male	0.36	0	NC*
Female	0.25	0	NC*
Total	0.61	0	NC*

#### **Breast**

Male	0.06	0	NC*
Female	6.74	6	89
Total	6.79	6	88

#### **Cervix Uteri**

Female	0.38	0	NC*
--------	------	---	-----

#### **Colon / Rectum**

Male	3.02	0	NC*
Female	2.27	0	NC*
Total	5.29	0	NC*

#### **Esophagus**

Male	0.45	0	NC*
Female	0.11	0	NC*
Total	0.56	0	NC*

#### **Hodgkin's Disease (Hodgkin Lymphoma)**

Male	0.17	0	NC*
Female	0.12	0	NC*

#### **Melanoma of Skin**

Male	0.82	0	NC*
Female	0.55	0	NC*
Total	1.37	0	NC*

#### **Multiple Myeloma**

Male	0.24	1	NC*
Female	0.18	0	NC*
Total	0.42	1	NC*

#### **Non-Hodgkin('s) Lymphoma**

Male	0.98	1	NC*
Female	0.73	1	NC*
Total	1.71	2	NC*

#### **Oral Cavity and Pharynx**

Male	0.79	2	NC*
Female	0.32	1	NC*
Total	1.11	3	NC*

#### **Ovary**

Female	0.78	0	NC*
--------	------	---	-----

#### **Pancreas**

Male	0.52	0	NC*
Female	0.42	1	NC*
Total	0.94	1	NC*

#### **Prostate**

Male	7.55	4	NC*
------	------	---	-----

Total	0.29	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	0.73	0	NC*	Male	0.52	0	NC*
Female	0.39	0	NC*	Female	0.24	0	NC*
Total	1.12	0	NC*	Total	0.76	0	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.42	0	NC*	Male	0.24	0	NC*
Female	0.09	0	NC*				
Total	0.52	0	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	0.56	0	NC*	Male	0.16	0	NC*
Female	0.37	0	NC*	Female	0.38	0	NC*
Total	0.94	0	NC*	Total	0.54	0	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.28	1	NC*				
Female	0.09	0	NC*	Female	1.32	0	NC*
Total	0.38	1	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	3.84	4	NC*	Male	24.56	15	61
Female	2.65	2	NC*	Female	20.12	13	65
Total	6.49	6	92	Total	44.68	28	63 #-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Gloucester

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	21.24	22	104	Male	13.69	11	80
Female	8.53	11	129	Female	10.66	15	141
Total	29.77	33	111	Total	24.35	26	107
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	6.00	10	167	Male	4.10	5	122
Female	5.03	4	NC*	Female	3.78	8	212
Total	11.03	14	127	Total	7.88	13	165
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.98	1	NC*	Male	16.60	11	66
Female	129.93	155	119 #+	Female	15.80	20	127
Total	130.91	156	119 #+	Total	32.40	31	96
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
				Male	12.80	19	148
Female	7.01	12	171	Female	6.54	6	92
				Total	19.34	25	129

**Colon / Rectum**

Male	52.57	47	89
Female	53.46	53	99
Total	106.03	100	94

**Esophagus**

Male	7.48	17	227 ~+
Female	2.61	2	NC*
Total	10.09	19	188 #+

**Hodgkin's Disease (Hodgkin Lymphoma)**

Male	2.92	4	NC*
Female	2.33	1	NC*
Total	5.25	5	95

**Kidney and Renal Pelvis**

Male	12.16	15	123
Female	8.00	13	162
Total	20.17	28	139

**Larynx**

Male	6.96	9	129
Female	1.83	3	NC*
Total	8.79	12	137

**Leukemia**

Male	9.70	14	144
Female	7.92	9	114
Total	17.62	23	131

**Liver and Intrahepatic Bile Ducts**

Male	4.73	8	169
Female	2.14	3	NC*
Total	6.87	11	160

**Lung and Bronchus**

Male	66.44	65	98
Female	55.51	61	110
Total	121.94	126	103

**Ovary**

Female	15.03	16	106
--------	-------	----	-----

**Pancreas**

Male	8.84	11	124
Female	9.87	11	112
Total	18.70	22	118

**Prostate**

Male	130.03	93	72 ^-
------	--------	----	-------

**Stomach**

Male	8.90	13	146
Female	5.79	6	104
Total	14.70	19	129

**Testis**

Male	4.31	7	162
------	------	---	-----

**Thyroid**

Male	2.62	1	NC*
Female	7.01	2	NC*
Total	9.63	3	NC*

**Uteri, Corpus and Uterus, NOS**

Female	25.25	32	127
--------	-------	----	-----

**All Sites / Types**

Male	421.41	410	97
Female	414.65	479	116 ~+
Total	836.06	889	106

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

**Goshen**

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	0.63	0	NC*	Male	0.42	0	NC*
Female	0.21	0	NC*	Female	0.30	0	NC*
Total	0.84	0	NC*	Total	0.72	0	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			

Male	0.19	2	NC*
Female	0.14	0	NC*
Total	0.32	2	NC*
<b>Breast</b>			
Male	0.03	0	NC*
Female	3.52	2	NC*
Total	3.55	2	NC*
<b>Cervix Uteri</b>			
Female	0.21	0	NC*
<b>Colon / Rectum</b>			
Male	1.57	2	NC*
Female	1.33	0	NC*
Total	2.91	2	NC*
<b>Esophagus</b>			
Male	0.23	0	NC*
Female	0.06	0	NC*
Total	0.30	0	NC*
<b>Hodgkin's Disease (Hodgkin Lymphoma)</b>			
Male	0.09	0	NC*
Female	0.07	0	NC*
Total	0.16	0	NC*
<b>Kidney and Renal Pelvis</b>			
Male	0.38	0	NC*
Female	0.21	0	NC*
Total	0.58	0	NC*
<b>Larynx</b>			
Male	0.22	0	NC*
Female	0.05	0	NC*
Total	0.27	0	NC*
<b>Leukemia</b>			
Male	0.29	0	NC*
Female	0.21	0	NC*
Total	0.50	0	NC*
<b>Liver and Intrahepatic Bile Ducts</b>			
Male	0.15	1	NC*
Female	0.05	0	NC*
Total	0.20	1	NC*
<b>Lung and Bronchus</b>			
Male	2.06	2	NC*
Female	1.41	2	NC*
Total	3.47	4	NC*

Male	0.12	0	NC*
Female	0.10	0	NC*
Total	0.22	0	NC*
<b>Non-Hodgkin('s) Lymphoma</b>			
Male	0.50	0	NC*
Female	0.41	0	NC*
Total	0.91	0	NC*
<b>Oral Cavity and Pharynx</b>			
Male	0.40	1	NC*
Female	0.17	0	NC*
Total	0.57	1	NC*
<b>Ovary</b>			
Female	0.41	0	NC*
<b>Pancreas</b>			
Male	0.27	0	NC*
Female	0.24	1	NC*
Total	0.51	1	NC*
<b>Prostate</b>			
Male	4.11	2	NC*
<b>Stomach</b>			
Male	0.26	0	NC*
Female	0.14	0	NC*
Total	0.41	0	NC*
<b>Testis</b>			
Male	0.12	0	NC*
<b>Thyroid</b>			
Male	0.08	1	NC*
Female	0.21	0	NC*
Total	0.29	1	NC*
<b>Uteri, Corpus and Uterus, NOS</b>			
Female	0.67	2	NC*
<b>All Sites / Types</b>			
Male	12.97	11	85
Female	10.91	7	64
Total	23.88	18	75

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Gosnold

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	0.18	0	NC*	Male	0.11	0	NC*
Female	0.04	0	NC*	Female	0.05	0	NC*
Total	0.22	0	NC*	Total	0.16	0	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.04	0	NC*	Male	0.03	0	NC*
Female	0.02	0	NC*	Female	0.02	0	NC*
Total	0.07	0	NC*	Total	0.05	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.01	0	NC*	Male	0.13	0	NC*
Female	0.66	0	NC*	Female	0.08	0	NC*
Total	0.67	0	NC*	Total	0.21	0	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	0.03	0	NC*	Male	0.10	0	NC*
				Female	0.03	0	NC*
				Total	0.14	0	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	0.44	0	NC*	Female	0.08	0	NC*
Female	0.27	0	NC*				
Total	0.72	0	NC*				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	0.06	0	NC*	Male	0.07	0	NC*
Female	0.01	0	NC*	Female	0.05	0	NC*
Total	0.08	0	NC*	Total	0.12	0	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.02	0	NC*	Male	1.14	0	NC*
Female	0.01	0	NC*				
Total	0.03	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	0.10	0	NC*	Male	0.07	0	NC*
Female	0.04	0	NC*	Female	0.03	0	NC*
Total	0.14	0	NC*	Total	0.10	0	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.06	0	NC*	Male	0.02	0	NC*
Female	0.01	0	NC*				
Total	0.07	0	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	0.07	0	NC*	Male	0.02	0	NC*
Female	0.04	0	NC*	Female	0.03	0	NC*
Total	0.11	0	NC*	Total	0.05	0	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.04	0	NC*	Female	0.13	0	NC*
Female	0.01	0	NC*				
Total	0.05	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	0.57	0	NC*	Male	3.51	0	NC*
Female	0.29	0	NC*	Female	2.12	0	NC*

Total	0.86	0	NC*	Total	5.63	0	NC*
-------	------	---	-----	-------	------	---	-----

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Grafton

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	8.45	3	NC*	Male	5.91	1	NC*
Female	3.15	2	NC*	Female	4.59	3	NC*
Total	11.60	5	43	Total	10.49	4	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	2.70	5	185	Male	1.68	2	NC*
Female	2.18	2	NC*	Female	1.46	4	NC*
Total	4.88	7	143	Total	3.15	6	191
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.41	2	NC*	Male	7.10	12	169
Female	53.99	65	120	Female	6.27	6	96
Total	54.40	67	123	Total	13.36	18	135
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	3.22	2	NC*	Male	5.55	4	NC*
				Female	2.62	4	NC*
				Total	8.17	8	98
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	21.08	9	43 ~-	Female	6.34	6	95
Female	19.79	20	101				
Total	40.88	29	71				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	3.12	0	NC*	Male	3.60	4	NC*
Female	0.96	0	NC*	Female	3.64	3	NC*
Total	4.08	0	NC*	Total	7.24	7	97
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	1.39	1	NC*	Male	53.23	62	116
Female	1.11	1	NC*				
Total	2.50	2	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	5.19	4	NC*	Male	3.60	3	NC*
Female	3.19	3	NC*	Female	2.13	1	NC*
Total	8.38	7	84	Total	5.73	4	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	2.96	2	NC*	Male	2.13	0	NC*
Female	0.74	0	NC*				
Total	3.70	2	NC*				



**Leukemia**

Male	4.14	2	NC*
Female	3.18	3	NC*
Total	7.32	5	68

**Liver and Intrahepatic Bile Ducts**

Male	2.01	3	NC*
Female	0.81	0	NC*
Total	2.81	3	NC*

**Lung and Bronchus**

Male	27.12	20	74
Female	21.80	19	87
Total	48.92	39	80

**Thyroid**

Male	1.22	2	NC*
Female	3.33	3	NC*
Total	4.55	5	110

**Uteri, Corpus and Uterus, NOS**

Female	10.39	6	58
--------	-------	---	----

**All Sites / Types**

Male	174.35	152	87
Female	166.66	163	98
Total	341.02	315	92

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

**Granby****Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999**

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	3.73	0	NC*	Male	2.62	1	NC*
Female	1.34	0	NC*	Female	1.98	1	NC*
Total	5.07	0	NC*	Total	4.60	2	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	1.20	1	NC*	Male	0.75	1	NC*
Female	0.95	3	NC*	Female	0.63	0	NC*
Total	2.15	4	NC*	Total	1.39	1	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.18	0	NC*	Male	3.12	1	NC*
Female	23.84	21	88	Female	2.70	2	NC*
Total	24.03	21	87	Total	5.82	3	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	1.39	0	NC*	Male	2.51	3	NC*
				Female	1.15	1	NC*
				Total	3.66	4	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	9.38	9	96	Female	2.79	0	NC*
Female	8.35	3	NC*				
Total	17.73	12	68				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	1.42	1	NC*	Male	1.61	1	NC*
Female	0.41	0	NC*	Female	1.57	1	NC*
Total	1.83	1	NC*	Total	3.18	2	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			

Male	0.59	1	NC*	Male	24.61	16	65
Female	0.47	1	NC*				
Total	1.06	2	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	2.33	2	NC*	Male	1.59	1	NC*
Female	1.41	1	NC*	Female	0.89	1	NC*
Total	3.74	3	NC*	Total	2.48	2	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	1.36	3	NC*	Male	0.88	4	NC*
Female	0.34	0	NC*				
Total	1.69	3	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	1.81	1	NC*	Male	0.54	1	NC*
Female	1.38	1	NC*	Female	1.42	2	NC*
Total	3.19	2	NC*	Total	1.96	3	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.91	0	NC*	Female	4.65	6	129
Female	0.35	0	NC*				
Total	1.26	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	12.33	7	57	Male	78.62	55	70 ~-
Female	9.68	8	83	Female	72.67	61	84
Total	22.01	15	68	Total	151.29	116	77 ~-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Granville

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>		<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	0.82	2	NC*	Male	0.61	0	NC*
Female	0.32	0	NC*	Female	0.46	0	NC*
Total	1.14	2	NC*	Total	1.07	0	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.29	0	NC*	Male	0.17	0	NC*
Female	0.21	0	NC*	Female	0.15	0	NC*
Total	0.50	0	NC*	Total	0.32	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.04	0	NC*	Male	0.72	0	NC*
Female	5.49	2	NC*	Female	0.62	0	NC*
Total	5.54	2	NC*	Total	1.34	0	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
				Male	0.60	0	NC*

Female	0.32	0	NC*
<b><u>Colon / Rectum</u></b>			
Male	2.08	3	NC*
Female	1.99	0	NC*
Total	4.07	3	NC*
<b><u>Esophagus</u></b>			
Male	0.33	0	NC*
Female	0.10	0	NC*
Total	0.43	0	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>			
Male	0.14	0	NC*
Female	0.11	0	NC*
Total	0.24	0	NC*
<b><u>Kidney and Renal Pelvis</u></b>			
Male	0.55	0	NC*
Female	0.32	0	NC*
Total	0.87	0	NC*
<b><u>Larynx</u></b>			
Male	0.32	0	NC*
Female	0.08	0	NC*
Total	0.40	0	NC*
<b><u>Leukemia</u></b>			
Male	0.42	0	NC*
Female	0.32	0	NC*
Total	0.74	0	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>			
Male	0.21	0	NC*
Female	0.08	0	NC*
Total	0.29	0	NC*
<b><u>Lung and Bronchus</u></b>			
Male	2.82	2	NC*
Female	2.16	3	NC*
Total	4.98	5	100

Female	0.27	0	NC*
Total	0.87	0	NC*
<b><u>Ovary</u></b>			
Female	0.64	1	NC*
<b><u>Pancreas</u></b>			
Male	0.36	0	NC*
Female	0.37	0	NC*
Total	0.73	0	NC*
<b><u>Prostate</u></b>			
Male	5.71	4	NC*
<b><u>Stomach</u></b>			
Male	0.35	1	NC*
Female	0.22	0	NC*
Total	0.57	1	NC*
<b><u>Testis</u></b>			
Male	0.20	1	NC*
<b><u>Thyroid</u></b>			
Male	0.13	0	NC*
Female	0.33	0	NC*
Total	0.45	0	NC*
<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Female	1.06	0	NC*
<b><u>All Sites / Types</u></b>			
Male	18.01	16	89
Female	16.80	6	36 ~-
Total	34.82	22	63 #-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Great Barrington

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	5.69	2	NC*	Male	3.71	4	NC*

Female	2.68	2	NC*
Total	8.37	4	NC*

#### **Brain and Other Central Nervous System**

Male	1.62	4	NC*
Female	1.47	0	NC*
Total	3.10	4	NC*

#### **Breast**

Male	0.27	1	NC*
Female	38.73	31	80
Total	39.00	32	82

#### **Cervix Uteri**

Female	2.03	3	NC*
--------	------	---	-----

#### **Colon / Rectum**

Male	14.05	17	121
Female	16.83	11	65
Total	30.88	28	91

#### **Esophagus**

Male	2.01	1	NC*
Female	0.82	1	NC*
Total	2.83	2	NC*

#### **Hodgkin's Disease (Hodgkin Lymphoma)**

Male	0.78	1	NC*
Female	0.67	0	NC*
Total	1.45	1	NC*

#### **Kidney and Renal Pelvis**

Male	3.32	4	NC*
Female	2.40	1	NC*
Total	5.71	5	88

#### **Larynx**

Male	1.88	1	NC*
Female	0.53	1	NC*
Total	2.42	2	NC*

#### **Leukemia**

Male	2.63	1	NC*
Female	2.44	3	NC*
Total	5.07	4	NC*

#### **Liver and Intrahepatic Bile Ducts**

Male	1.28	0	NC*
Female	0.66	0	NC*
Total	1.94	0	NC*

#### **Lung and Bronchus**

Male	17.75	15	85
Female	16.44	14	85
Total	34.19	29	85

Female	3.18	0	NC*
Total	6.89	4	NC*

#### **Multiple Myeloma**

Male	1.11	0	NC*
Female	1.16	0	NC*
Total	2.27	0	NC*

#### **Non-Hodgkin('s) Lymphoma**

Male	4.48	5	112
Female	4.79	4	NC*
Total	9.27	9	97

#### **Oral Cavity and Pharynx**

Male	3.49	1	NC*
Female	1.98	1	NC*
Total	5.47	2	NC*

#### **Ovary**

Female	4.45	4	NC*
--------	------	---	-----

#### **Pancreas**

Male	2.37	6	254
Female	3.06	2	NC*
Total	5.43	8	147

#### **Prostate**

Male	34.49	32	93
------	-------	----	----

#### **Stomach**

Male	2.39	3	NC*
Female	1.85	0	NC*
Total	4.24	3	NC*

#### **Testis**

Male	1.13	0	NC*
------	------	---	-----

#### **Thyroid**

Male	0.71	0	NC*
Female	2.01	1	NC*
Total	2.72	1	NC*

#### **Uteri, Corpus and Uterus, NOS**

Female	7.47	6	80
--------	------	---	----

#### **All Sites / Types**

Male	112.77	106	94
Female	125.25	98	78 #--
Total	238.02	204	86 #--

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Greenfield

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	12.90	11	85	Male	8.08	9	111
Female	5.91	4	NC*	Female	6.84	7	102
Total	18.81	15	80	Total	14.92	16	107
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	3.51	4	NC*	Male	2.45	2	NC*
Female	3.20	6	188	Female	2.51	1	NC*
Total	6.70	10	149	Total	4.97	3	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.59	2	NC*	Male	9.88	9	91
Female	82.01	83	101	Female	10.48	13	124
Total	82.59	85	103	Total	20.35	22	108
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	4.37	3	NC*	Male	7.44	5	67
				Female	4.25	2	NC*
				Total	11.69	7	60
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	31.69	31	98	Female	9.48	12	127
Female	37.26	41	110				
Total	68.95	72	104				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	4.38	1	NC*	Male	5.27	7	133
Female	1.81	1	NC*	Female	6.76	11	163
Total	6.20	2	NC*	Total	12.03	18	150
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	1.70	1	NC*	Male	75.84	53	70 ~-
Female	1.50	3	NC*				
Total	3.20	4	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	7.17	6	84	Male	5.38	4	NC*
Female	5.16	8	155	Female	4.09	3	NC*
Total	12.33	14	114	Total	9.47	7	74
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	4.04	3	NC*	Male	2.51	3	NC*
Female	1.12	1	NC*				
Total	5.16	4	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	5.83	4	NC*	Male	1.51	0	NC*
Female	5.30	10	189	Female	4.36	5	115
Total	11.13	14	126	Total	5.87	5	85
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	2.77	3	NC*	Female	15.70	18	115
Female	1.44	0	NC*				

Total	4.22	3	NC*
<b><u>Lung and Bronchus</u></b>			
Male	39.31	44	112
Female	35.48	35	99
Total	74.80	79	106

**All Sites / Types**

Male	249.35	226	91
Female	270.10	288	107
Total	519.46	514	99

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Groton

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>			
Male	4.54	11	242 #+
Female	1.53	0	NC*
Total	6.07	11	181

**Brain and Other Central Nervous System**

Male	1.69	2	NC*
Female	1.25	0	NC*
Total	2.94	2	NC*

**Breast**

Male	0.23	0	NC*
Female	31.34	26	83
Total	31.57	26	82

**Cervix Uteri**

Female	1.94	4	NC*
--------	------	---	-----

**Colon / Rectum**

Male	11.47	5	44
Female	9.59	6	63
Total	21.06	11	52 #-

**Esophagus**

Male	1.87	1	NC*
Female	0.46	1	NC*
Total	2.33	2	NC*

**Hodgkin's Disease (Hodgkin Lymphoma)**

Male	0.86	0	NC*
Female	0.65	1	NC*
Total	1.51	1	NC*

**Kidney and Renal Pelvis**

Male	3.13	2	NC*
Female	1.73	2	NC*
Total	4.86	4	NC*

**Melanoma of Skin**

Male	3.56	4	NC*
Female	2.67	1	NC*
Total	6.22	5	80

**Multiple Myeloma**

Male	0.96	0	NC*
Female	0.76	1	NC*
Total	1.72	1	NC*

**Non-Hodgkin('s) Lymphoma**

Male	4.19	2	NC*
Female	3.28	1	NC*
Total	7.47	3	NC*

**Oral Cavity and Pharynx**

Male	3.51	4	NC*
Female	1.45	1	NC*
Total	4.96	5	101

**Ovary**

Female	3.68	4	NC*
--------	------	---	-----

**Pancreas**

Male	2.05	1	NC*
Female	1.76	1	NC*
Total	3.81	2	NC*

**Prostate**

Male	30.48	27	89
------	-------	----	----

**Stomach**

Male	2.02	0	NC*
Female	1.03	0	NC*
Total	3.05	0	NC*

**Larynx**

Male	1.81	0	NC*
Female	0.42	0	NC*
Total	2.23	0	NC*

**Leukemia**

Male	2.42	1	NC*
Female	1.76	3	NC*
Total	4.18	4	NC*

**Liver and Intrahepatic Bile Ducts**

Male	1.21	0	NC*
Female	0.40	0	NC*
Total	1.61	0	NC*

**Lung and Bronchus**

Male	15.19	9	59
Female	11.41	7	61
Total	26.60	16	60 #-

**Testis**

Male	1.28	2	NC*
------	------	---	-----

**Thyroid**

Male	0.78	1	NC*
Female	2.03	1	NC*
Total	2.81	2	NC*

**Uteri, Corpus and Uterus, NOS**

Female	6.03	1	NC*
--------	------	---	-----

**All Sites / Types**

Male	99.85	73	73 ~-
Female	91.27	65	71 ~-
Total	191.12	138	72 ^-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Groveland

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	3.22	5	155	Male	2.40	0	NC*
Female	1.17	1	NC*	Female	1.79	3	NC*
Total	4.39	6	137	Total	4.19	3	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	1.13	1	NC*	Male	0.67	0	NC*
Female	0.85	0	NC*	Female	0.56	0	NC*
Total	1.98	1	NC*	Total	1.23	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.16	0	NC*	Male	2.84	5	176
Female	21.56	22	102	Female	2.37	2	NC*
Total	21.72	22	101	Total	5.21	7	134
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	1.26	2	NC*	Male	2.32	0	NC*
				Female	1.03	0	NC*
				Total	3.34	0	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	8.15	9	110	Female	2.52	1	NC*
Female	7.28	6	82				
Total	15.43	15	97				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			

Male	1.27	1	NC*	Male	1.42	0	NC*
Female	0.35	0	NC*	Female	1.35	2	NC*
Total	1.63	1	NC*	Total	2.77	2	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.57	1	NC*	Male	21.70	16	74
Female	0.42	3	NC*				
Total	0.99	4	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	2.13	3	NC*	Male	1.39	2	NC*
Female	1.24	1	NC*	Female	0.78	1	NC*
Total	3.37	4	NC*	Total	2.17	3	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	1.23	2	NC*	Male	0.86	2	NC*
Female	0.30	0	NC*				
Total	1.53	2	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	1.65	2	NC*	Male	0.51	1	NC*
Female	1.24	1	NC*	Female	1.29	1	NC*
Total	2.89	3	NC*	Total	1.80	2	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.82	0	NC*	Female	4.19	6	143
Female	0.30	0	NC*				
Total	1.13	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	10.86	10	92	Male	69.87	61	87
Female	8.41	10	119	Female	64.70	65	100
Total	19.27	20	104	Total	134.58	126	94

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Hadley

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	3.72	3	NC*	Male	2.33	2	NC*
Female	1.47	2	NC*	Female	1.75	3	NC*
Total	5.19	5	96	Total	4.08	5	122
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.99	0	NC*	Male	0.71	0	NC*
Female	0.83	1	NC*	Female	0.65	0	NC*
Total	1.83	1	NC*	Total	1.36	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.17	0	NC*	Male	2.83	4	NC*



Female	21.63	26	120
Total	21.80	26	119

#### Cervix Uteri

Female	1.12	0	NC*
--------	------	---	-----

#### Colon / Rectum

Male	9.15	9	98
Female	9.27	6	65
Total	18.42	15	81

#### Esophagus

Male	1.26	0	NC*
Female	0.45	0	NC*
Total	1.71	0	NC*

#### Hodgkin's Disease (Hodgkin Lymphoma)

Male	0.48	1	NC*
Female	0.37	0	NC*
Total	0.85	1	NC*

#### Kidney and Renal Pelvis

Male	2.08	1	NC*
Female	1.36	0	NC*
Total	3.43	1	NC*

#### Larynx

Male	1.17	1	NC*
Female	0.31	0	NC*
Total	1.48	1	NC*

#### Leukemia

Male	1.65	0	NC*
Female	1.31	1	NC*
Total	2.96	1	NC*

#### Liver and Intrahepatic Bile Ducts

Male	0.80	1	NC*
Female	0.37	0	NC*
Total	1.17	1	NC*

#### Lung and Bronchus

Male	11.46	7	61
Female	9.57	6	63
Total	21.03	13	62

Female	2.70	4	NC*
Total	5.53	8	145

#### Oral Cavity and Pharynx

Male	2.14	2	NC*
Female	1.10	1	NC*
Total	3.24	3	NC*

#### Ovary

Female	2.49	3	NC*
--------	------	---	-----

#### Pancreas

Male	1.51	1	NC*
Female	1.70	0	NC*
Total	3.22	1	NC*

#### Prostate

Male	22.04	18	82
------	-------	----	----

#### Stomach

Male	1.53	1	NC*
Female	0.99	0	NC*
Total	2.53	1	NC*

#### Testis

Male	0.74	0	NC*
------	------	---	-----

#### Thyroid

Male	0.43	0	NC*
Female	1.11	1	NC*
Total	1.54	1	NC*

#### Uteri, Corpus and Uterus, NOS

Female	4.24	4	NC*
--------	------	---	-----

#### All Sites / Types

Male	72.10	59	82
Female	70.01	62	89
Total	142.11	121	85

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Halifax

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>			
Male	4.23	6	142
Female	1.79	2	NC*
Total	6.02	8	133
<b><u>Brain and Other Central Nervous System</u></b>			
Male	1.35	3	NC*
Female	1.16	2	NC*
Total	2.51	5	199
<b><u>Breast</u></b>			
Male	0.21	0	NC*
Female	29.60	31	105
Total	29.80	31	104
<b><u>Cervix Uteri</u></b>			
Female	1.68	3	NC*
<b><u>Colon / Rectum</u></b>			
Male	10.55	17	161
Female	11.24	8	71
Total	21.78	25	115
<b><u>Esophagus</u></b>			
Male	1.59	0	NC*
Female	0.54	1	NC*
Total	2.13	1	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>			
Male	0.67	0	NC*
Female	0.56	1	NC*
Total	1.23	1	NC*
<b><u>Kidney and Renal Pelvis</u></b>			
Male	2.64	4	NC*
Female	1.75	1	NC*
Total	4.39	5	114
<b><u>Larynx</u></b>			
Male	1.51	2	NC*
Female	0.40	0	NC*
Total	1.91	2	NC*
<b><u>Leukemia</u></b>			
Male	2.07	5	241
Female	1.76	1	NC*
Total	3.84	6	156
<b><u>Liver and Intrahepatic Bile Ducts</u></b>			
Male	1.02	1	NC*
Female	0.45	0	NC*
Total	1.47	1	NC*
<b><u>Lung and Bronchus</u></b>			
Male	13.57	17	125
Female	11.95	12	100
Total	25.52	29	114

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Melanoma of Skin</u></b>			
Male	2.98	2	NC*
Female	2.47	4	NC*
Total	5.45	6	110
<b><u>Multiple Myeloma</u></b>			
Male	0.85	1	NC*
Female	0.82	1	NC*
Total	1.67	2	NC*
<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	3.56	5	140
Female	3.44	2	NC*
Total	7.00	7	100
<b><u>Oral Cavity and Pharynx</u></b>			
Male	2.84	5	176
Female	1.45	2	NC*
Total	4.29	7	163
<b><u>Ovary</u></b>			
Female	3.44	1	NC*
<b><u>Pancreas</u></b>			
Male	1.81	3	NC*
Female	2.05	4	NC*
Total	3.87	7	181
<b><u>Prostate</u></b>			
Male	26.61	30	113
<b><u>Stomach</u></b>			
Male	1.81	4	NC*
Female	1.22	0	NC*
Total	3.03	4	NC*
<b><u>Testis</u></b>			
Male	1.01	0	NC*
<b><u>Thyroid</u></b>			
Male	0.61	1	NC*
Female	1.71	0	NC*
Total	2.32	1	NC*
<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Female	5.71	6	105
<b><u>All Sites / Types</u></b>			
Male	87.34	111	127 #+
Female	91.84	87	95
Total	179.18	198	111

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Hamilton

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	5.31	6	113	Male	3.71	6	162
Female	1.81	1	NC*	Female	2.70	3	NC*
Total	7.12	7	98	Total	6.42	9	140
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	1.69	2	NC*	Male	1.07	0	NC*
Female	1.28	2	NC*	Female	0.86	1	NC*
Total	2.96	4	NC*	Total	1.93	1	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.26	0	NC*	Male	4.42	6	136
Female	32.89	27	82	Female	3.65	4	NC*
Total	33.15	27	81	Total	8.07	10	124
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	1.88	2	NC*	Male	3.58	2	NC*
				Female	1.57	1	NC*
				Total	5.15	3	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	13.32	7	53	Female	3.83	3	NC*
Female	11.28	9	80				
Total	24.61	16	65				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	2.02	0	NC*	Male	2.29	4	NC*
Female	0.55	0	NC*	Female	2.11	2	NC*
Total	2.57	0	NC*	Total	4.40	6	136
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.82	1	NC*	Male	34.82	33	95
Female	0.61	2	NC*				
Total	1.43	3	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	3.32	2	NC*	Male	2.26	1	NC*
Female	1.91	0	NC*	Female	1.21	2	NC*
Total	5.23	2	NC*	Total	3.47	3	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	1.93	2	NC*	Male	1.21	2	NC*
Female	0.46	0	NC*				
Total	2.39	2	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	2.57	4	NC*	Male	0.75	0	NC*
Female	1.86	3	NC*	Female	1.92	0	NC*
Total	4.43	7	158	Total	2.67	0	NC*

**Liver and Intrahepatic Bile Ducts**

Male	1.29	0	NC*
Female	0.47	1	NC*
Total	1.76	1	NC*

**Lung and Bronchus**

Male	17.47	10	57
Female	13.10	8	61
Total	30.57	18	59 #-

**Uteri, Corpus and Uterus, NOS**

Female	6.43	7	109
--------	------	---	-----

**All Sites / Types**

Male	111.38	98	88
Female	99.16	82	83
Total	210.55	180	85 #-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

**Hampden****Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999**

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	2.99	2	NC*	Male	2.14	2	NC*
Female	1.17	0	NC*	Female	1.64	2	NC*
Total	4.16	2	NC*	Total	3.78	4	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.96	1	NC*	Male	0.61	2	NC*
Female	0.75	1	NC*	Female	0.54	0	NC*
Total	1.72	2	NC*	Total	1.15	2	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.15	0	NC*	Male	2.53	2	NC*
Female	20.09	21	105	Female	2.24	2	NC*
Total	20.24	21	104	Total	4.76	4	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	1.11	1	NC*	Male	2.09	2	NC*
				Female	0.98	0	NC*
				Total	3.07	2	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	7.52	5	67	Female	2.31	0	NC*
Female	7.29	3	NC*				
Total	14.81	8	54				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	1.17	1	NC*	Male	1.31	2	NC*
Female	0.35	2	NC*	Female	1.34	0	NC*
Total	1.52	3	NC*	Total	2.65	2	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.46	0	NC*	Male	19.77	23	116
Female	0.35	0	NC*				
Total	0.81	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			

Male	1.91	2	NC*
Female	1.17	0	NC*
Total	3.08	2	NC*

#### Larynx

Male	1.12	1	NC*
Female	0.27	0	NC*
Total	1.39	1	NC*

#### Leukemia

Male	1.45	2	NC*
Female	1.17	4	NC*
Total	2.62	6	229

#### Liver and Intrahepatic Bile Ducts

Male	0.74	1	NC*
Female	0.30	0	NC*
Total	1.04	1	NC*

#### Lung and Bronchus

Male	9.88	8	81
Female	7.84	8	102
Total	17.72	16	90

Male	1.29	4	NC*
Female	0.80	0	NC*
Total	2.09	4	NC*

#### Testis

Male	0.67	0	NC*
------	------	---	-----

#### Thyroid

Male	0.44	0	NC*
Female	1.11	3	NC*
Total	1.55	3	NC*

#### Uteri, Corpus and Uterus, NOS

Female	3.90	2	NC*
--------	------	---	-----

#### All Sites / Types

Male	63.31	62	98
Female	61.07	49	80
Total	124.38	111	89

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Hancock

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>			
Male	0.52	0	NC*
Female	0.16	0	NC*
Total	0.68	0	NC*

#### **Brain and Other Central Nervous System**

Male	0.15	0	NC*
Female	0.11	0	NC*
Total	0.27	0	NC*

#### **Breast**

Male	0.02	0	NC*
Female	3.03	1	NC*
Total	3.05	1	NC*

#### **Cervix Uteri**

Female	0.17	0	NC*
--------	------	---	-----

#### **Colon / Rectum**

Male	1.29	2	NC*
------	------	---	-----

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Melanoma of Skin</u></b>			
Male	0.35	1	NC*
Female	0.25	0	NC*
Total	0.59	1	NC*

#### **Multiple Myeloma**

Male	0.10	1	NC*
Female	0.08	0	NC*
Total	0.18	1	NC*

#### **Non-Hodgkin('s) Lymphoma**

Male	0.41	0	NC*
Female	0.33	0	NC*
Total	0.74	0	NC*

#### **Oral Cavity and Pharynx**

Male	0.33	0	NC*
Female	0.14	0	NC*
Total	0.47	0	NC*

#### **Ovary**

Female	0.99	0	NC*	Female	0.35	0	NC*
Total	2.28	2	NC*				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	0.19	0	NC*	Male	0.22	1	NC*
Female	0.05	0	NC*	Female	0.18	0	NC*
Total	0.24	0	NC*	Total	0.40	1	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.07	0	NC*	Male	3.24	1	NC*
Female	0.05	0	NC*				
Total	0.12	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	0.31	1	NC*	Male	0.22	0	NC*
Female	0.17	0	NC*	Female	0.10	0	NC*
Total	0.49	1	NC*	Total	0.32	0	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.18	0	NC*	Male	0.10	0	NC*
Female	0.04	0	NC*				
Total	0.22	0	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	0.24	0	NC*	Male	0.07	0	NC*
Female	0.16	0	NC*	Female	0.18	0	NC*
Total	0.40	0	NC*	Total	0.24	0	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	0.12	0	NC*	Female	0.60	1	NC*
Female	0.04	0	NC*				
Total	0.16	0	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	1.66	0	NC*	Male	10.49	7	67
Female	1.19	1	NC*	Female	8.98	3	NC*
Total	2.86	1	NC*	Total	19.47	10	51 #-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Hanover

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	6.98	6	86	Male	5.36	8	149
Female	2.74	4	NC*	Female	4.24	7	165
Total	9.72	10	103	Total	9.60	15	156
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	2.53	0	NC*	Male	1.47	1	NC*
Female	2.01	5	249	Female	1.33	1	NC*

Total	4.54	5	110
<b>Breast</b>			
Male	0.36	1	NC*
Female	51.63	54	105
Total	51.99	55	106

**Cervix Uteri**

Female	2.97	3	NC*
--------	------	---	-----

**Colon / Rectum**

Male	17.73	19	107
Female	17.09	20	117
Total	34.82	39	112

**Esophagus**

Male	2.86	5	175
Female	0.83	0	NC*
Total	3.68	5	136

**Hodgkin's Disease (Hodgkin Lymphoma)**

Male	1.28	0	NC*
Female	0.96	1	NC*
Total	2.24	1	NC*

**Kidney and Renal Pelvis**

Male	4.76	6	126
Female	2.96	1	NC*
Total	7.72	7	91

**Larynx**

Male	2.78	2	NC*
Female	0.72	0	NC*
Total	3.50	2	NC*

**Leukemia**

Male	3.63	4	NC*
Female	2.89	3	NC*
Total	6.53	7	107

**Liver and Intrahepatic Bile Ducts**

Male	1.84	0	NC*
Female	0.72	0	NC*
Total	2.56	0	NC*

**Lung and Bronchus**

Male	23.90	14	59 #-
Female	20.23	31	153 #+
Total	44.13	45	102

Total	2.80	2	NC*
<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	6.30	5	79
Female	5.62	6	107
Total	11.92	11	92

**Oral Cavity and Pharynx**

Male	5.25	5	95
Female	2.45	5	204
Total	7.70	10	130

**Ovary**

Female	6.01	4	NC*
--------	------	---	-----

**Pancreas**

Male	3.12	1	NC*
Female	3.19	1	NC*
Total	6.31	2	NC*

**Prostate**

Male	48.18	56	116
------	-------	----	-----

**Stomach**

Male	3.04	2	NC*
Female	1.82	2	NC*
Total	4.86	4	NC*

**Testis**

Male	1.93	1	NC*
------	------	---	-----

**Thyroid**

Male	1.16	1	NC*
Female	3.03	5	165
Total	4.20	6	143

**Uteri, Corpus and Uterus, NOS**

Female	10.11	11	109
--------	-------	----	-----

**All Sites / Types**

Male	154.48	142	92
Female	153.92	179	116
Total	308.40	321	104

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

# Hanson

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	4.97	5	101	Male	3.77	1	NC*
Female	1.87	5	268	Female	2.92	4	NC*
Total	6.83	10	146	Total	6.69	5	75
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	1.77	2	NC*	Male	1.03	0	NC*
Female	1.39	0	NC*	Female	0.89	1	NC*
Total	3.16	2	NC*	Total	1.93	1	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.25	0	NC*	Male	4.46	0	NC*
Female	34.78	37	106	Female	3.82	2	NC*
Total	35.03	37	106	Total	8.28	2	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	2.07	2	NC*	Male	3.66	3	NC*
				Female	1.65	5	303
				Total	5.31	8	151
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	12.54	15	120	Female	4.07	3	NC*
Female	11.69	7	60				
Total	24.23	22	91				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	1.99	1	NC*	Male	2.20	3	NC*
Female	0.56	0	NC*	Female	2.15	1	NC*
Total	2.55	1	NC*	Total	4.36	4	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.91	1	NC*	Male	33.19	32	96
Female	0.69	3	NC*				
Total	1.60	4	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	3.32	0	NC*	Male	2.17	0	NC*
Female	1.99	2	NC*	Female	1.26	0	NC*
Total	5.30	2	NC*	Total	3.43	0	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	1.92	2	NC*	Male	1.39	3	NC*
Female	0.47	0	NC*				
Total	2.39	2	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	2.57	2	NC*	Male	0.82	3	NC*
Female	2.01	2	NC*	Female	2.14	3	NC*
Total	4.58	4	NC*	Total	2.96	6	203
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	1.28	1	NC*	Female	6.73	8	119
Female	0.49	0	NC*				
Total	1.77	1	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	16.59	18	108	Male	107.92	97	90
Female	13.39	9	67	Female	104.19	99	95
Total	29.98	27	90	Total	212.11	196	92



**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Hardwick

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	1.76	3	NC*	Male	1.16	0	NC*
Female	0.69	0	NC*	Female	0.88	1	NC*
Total	2.45	3	NC*	Total	2.04	1	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.52	0	NC*	Male	0.34	0	NC*
Female	0.42	0	NC*	Female	0.31	0	NC*
Total	0.94	0	NC*	Total	0.65	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.08	0	NC*	Male	1.41	1	NC*
Female	10.40	12	115	Female	1.30	4	NC*
Total	10.48	12	115	Total	2.71	5	184
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	0.59	2	NC*	Male	1.08	0	NC*
				Female	0.52	0	NC*
				Total	1.60	0	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	4.35	4	NC*	Female	1.22	2	NC*
Female	4.40	4	NC*				
Total	8.75	8	91				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	0.62	1	NC*	Male	0.73	0	NC*
Female	0.21	0	NC*	Female	0.80	0	NC*
Total	0.83	1	NC*	Total	1.53	0	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.26	0	NC*	Male	10.58	9	85
Female	0.21	0	NC*				
Total	0.47	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	1.03	0	NC*	Male	0.74	0	NC*
Female	0.64	0	NC*	Female	0.47	2	NC*
Total	1.67	0	NC*	Total	1.22	2	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.58	0	NC*	Male	0.39	0	NC*
Female	0.14	0	NC*				
Total	0.72	0	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			

Male	0.83	0	NC*
Female	0.65	0	NC*
Total	1.48	0	NC*

#### Liver and Intrahepatic Bile Ducts

Male	0.40	0	NC*
Female	0.17	0	NC*
Total	0.57	0	NC*

#### Lung and Bronchus

Male	5.46	5	92
Female	4.44	6	135
Total	9.90	11	111

Male	0.23	0	NC*
Female	0.60	0	NC*
Total	0.83	0	NC*

#### Uteri, Corpus and Uterus, NOS

Female	2.00	5	250
--------	------	---	-----

#### All Sites / Types

Male	34.95	25	72
Female	33.57	41	122
Total	68.53	66	96

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Harvard

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<u>Bladder, Urinary</u>			
Male	3.95	2	NC*
Female	1.02	1	NC*
Total	4.97	3	NC*

#### Brain and Other Central Nervous System

Male	2.17	4	NC*
Female	1.24	1	NC*
Total	3.40	5	147

#### Breast

Male	0.21	0	NC*
Female	26.70	23	86
Total	26.92	23	85

#### Cervix Uteri

Female	2.11	1	NC*
--------	------	---	-----

#### Colon / Rectum

Male	10.22	3	NC*
Female	6.40	10	156
Total	16.62	13	78

#### Esophagus

Male	1.69	0	NC*
Female	0.30	1	NC*
Total	1.99	1	NC*

#### Hodgkin's Disease (Hodgkin Lymphoma)

Male	1.54	0	NC*
------	------	---	-----

#### Melanoma of Skin

Male	4.07	5	123
Female	2.57	2	NC*
Total	6.64	7	105

#### Multiple Myeloma

Male	0.86	0	NC*
Female	0.55	0	NC*
Total	1.41	0	NC*

#### Non-Hodgkin('s) Lymphoma

Male	4.86	1	NC*
Female	2.68	3	NC*
Total	7.54	4	NC*

#### Oral Cavity and Pharynx

Male	3.55	1	NC*
Female	1.17	1	NC*
Total	4.71	2	NC*

#### Ovary

Female	3.30	2	NC*
--------	------	---	-----

#### Pancreas

Male	1.84	1	NC*
Female	1.18	1	NC*
Total	3.02	2	NC*

#### Prostate

Male	25.91	19	73
------	-------	----	----

Female	0.81	0	NC*
Total	2.35	0	NC*

#### **Kidney and Renal Pelvis**

Male	3.12	3	NC*
Female	1.38	0	NC*
Total	4.50	3	NC*

#### **Larynx**

Male	1.68	1	NC*
Female	0.33	0	NC*
Total	2.01	1	NC*

#### **Leukemia**

Male	2.73	2	NC*
Female	1.54	1	NC*
Total	4.27	3	NC*

#### **Liver and Intrahepatic Bile Ducts**

Male	1.19	0	NC*
Female	0.29	0	NC*
Total	1.48	0	NC*

#### **Lung and Bronchus**

Male	13.42	5	37 #-
Female	8.54	7	82
Total	21.96	12	55 #-

#### **Stomach**

Male	1.84	0	NC*
Female	0.71	0	NC*
Total	2.55	0	NC*

#### **Testis**

Male	2.87	0	NC*
------	------	---	-----

#### **Thyroid**

Male	1.15	0	NC*
Female	2.36	3	NC*
Total	3.52	3	NC*

#### **Uteri, Corpus and Uterus, NOS**

Female	4.88	3	NC*
--------	------	---	-----

#### **All Sites / Types**

Male	96.10	49	51 ^-
Female	74.70	63	84
Total	170.79	112	66 ^-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## **Harwich**

### **Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999**

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>		<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	14.79	18	122	Male	7.56	14	185 #+
Female	5.64	12	213 #+	Female	5.43	13	239 ~+
Total	20.43	30	147	Total	12.99	27	208 ^+
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	2.88	5	174	Male	2.62	5	191
Female	2.59	1	NC*	Female	2.36	1	NC*
Total	5.47	6	110	Total	4.98	6	120
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.62	0	NC*	Male	9.53	11	115
Female	69.80	101	145 ^+	Female	9.48	16	169
Total	70.42	101	143 ^+	Total	19.01	27	142
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	3.08	2	NC*	Male	6.76	7	104
				Female	3.77	10	266 #+

				Total	10.53	17	162
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	35.47	29	82				
Female	35.62	46	129	Female	7.90	12	152
Total	71.09	75	105				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	4.39	5	114	Male	5.67	11	194
Female	1.75	1	NC*	Female	6.50	8	123
Total	6.13	6	98	Total	12.17	19	156
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	1.12	0	NC*	Male	78.03	144	185 ^+
Female	0.98	0	NC*				
Total	2.10	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	6.92	12	173	Male	5.96	7	117
Female	4.67	4	NC*	Female	3.85	3	NC*
Total	11.59	16	138	Total	9.81	10	102
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	3.83	7	183	Male	1.31	1	NC*
Female	1.02	1	NC*				
Total	4.85	8	165				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	5.78	5	86	Male	1.06	1	NC*
Female	4.56	5	110	Female	2.84	3	NC*
Total	10.34	10	97	Total	3.91	4	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	2.68	3	NC*				
Female	1.36	0	NC*	Female	13.76	20	145
Total	4.04	3	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	41.59	41	99	Male	256.52	347	135 ^+
Female	33.45	35	105	Female	239.62	311	130 ^+
Total	75.04	76	101	Total	496.14	658	133 ^+

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Hatfield

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	2.37	2	NC*	Male	1.53	0	NC*
Female	0.99	2	NC*	Female	1.20	0	NC*
Total	3.36	4	NC*	Total	2.73	0	NC*

**Brain and Other Central Nervous System**

Male	0.66	1	NC*
Female	0.58	2	NC*
Total	1.23	3	NC*

**Breast**

Male	0.11	0	NC*
Female	14.98	14	93
Total	15.09	14	93

**Cervix Uteri**

Female	0.77	1	NC*
--------	------	---	-----

**Colon / Rectum**

Male	5.84	5	86
Female	6.23	3	NC*
Total	12.08	8	66

**Esophagus**

Male	0.83	0	NC*
Female	0.30	0	NC*
Total	1.14	0	NC*

**Hodgkin's Disease (Hodgkin Lymphoma)**

Male	0.31	1	NC*
Female	0.25	0	NC*
Total	0.56	1	NC*

**Kidney and Renal Pelvis**

Male	1.37	1	NC*
Female	0.93	0	NC*
Total	2.30	1	NC*

**Larynx**

Male	0.78	1	NC*
Female	0.21	0	NC*
Total	0.99	1	NC*

**Leukemia**

Male	1.07	0	NC*
Female	0.89	1	NC*
Total	1.97	1	NC*

**Liver and Intrahepatic Bile Ducts**

Male	0.53	1	NC*
Female	0.25	0	NC*
Total	0.78	1	NC*

**Lung and Bronchus**

Male	7.39	8	108
Female	6.57	2	NC*
Total	13.96	10	72

**Multiple Myeloma**

Male	0.46	0	NC*
Female	0.45	0	NC*
Total	0.91	0	NC*

**Non-Hodgkin('s) Lymphoma**

Male	1.84	0	NC*
Female	1.84	2	NC*
Total	3.67	2	NC*

**Oral Cavity and Pharynx**

Male	1.43	4	NC*
Female	0.75	0	NC*
Total	2.19	4	NC*

**Ovary**

Female	1.73	0	NC*
--------	------	---	-----

**Pancreas**

Male	0.98	0	NC*
Female	1.14	0	NC*
Total	2.12	0	NC*

**Prostate**

Male	14.32	8	56
------	-------	---	----

**Stomach**

Male	0.99	0	NC*
Female	0.66	1	NC*
Total	1.65	1	NC*

**Testis**

Male	0.45	0	NC*
------	------	---	-----

**Thyroid**

Male	0.29	1	NC*
Female	0.76	1	NC*
Total	1.05	2	NC*

**Uteri, Corpus and Uterus, NOS**

Female	2.95	5	170
--------	------	---	-----

**All Sites / Types**

Male	46.68	36	77
Female	47.96	40	83
Total	94.64	76	80

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the **p** ≤ 0.05 level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Haverhill

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	29.14	32	110	Male	20.49	11	54 #~
Female	13.29	15	113	Female	17.83	12	67
Total	42.43	47	111	Total	38.31	23	60 #~
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	9.56	10	105	Male	5.70	5	88
Female	8.49	5	59	Female	5.84	3	NC*
Total	18.06	15	83	Total	11.55	8	69
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	1.38	0	NC*	Male	24.91	18	72
Female	205.43	194	94	Female	25.23	32	127
Total	206.80	194	94	Total	50.14	50	100
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	12.28	12	98	Male	18.58	21	113
				Female	10.28	14	136
				Total	28.86	35	121
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	72.49	69	95	Female	24.20	30	124
Female	83.78	86	103				
Total	156.27	155	99				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	10.42	13	125	Male	12.24	14	114
Female	4.06	7	172	Female	15.26	8	52
Total	14.49	20	138	Total	27.50	22	80
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	5.33	9	169	Male	177.30	156	88
Female	4.44	7	158				
Total	9.77	16	164				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	17.55	24	137	Male	12.37	11	89
Female	12.49	12	96	Female	9.19	14	152
Total	30.04	36	120	Total	21.56	25	116
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	9.80	6	61	Male	8.68	5	58
Female	2.76	2	NC*				
Total	12.56	8	64				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	14.61	14	96	Male	4.38	2	NC*
Female	13.05	17	130	Female	12.76	10	78
Total	27.66	31	112	Total	17.15	12	70
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	6.77	8	118	Female	38.89	45	116
Female	3.33	4	NC*				
Total	10.10	12	119				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	91.60	102	111	Male	594.78	562	94

Female	84.62	80	95	Female	656.64	656	100
Total	176.22	182	103	Total	1251.42	1218	97

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Hawley

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	0.36	1	NC*	Male	0.20	0	NC*
Female	0.09	1	NC*	Female	0.11	0	NC*
Total	0.45	2	NC*	Total	0.31	0	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.08	0	NC*	Male	0.07	0	NC*
Female	0.05	0	NC*	Female	0.04	0	NC*
Total	0.13	0	NC*	Total	0.11	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.02	1	NC*	Male	0.25	0	NC*
Female	1.41	3	NC*	Female	0.17	0	NC*
Total	1.42	4	NC*	Total	0.42	0	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	0.07	0	NC*	Male	0.19	0	NC*
				Female	0.07	0	NC*
				Total	0.26	0	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	0.87	0	NC*	Female	0.16	0	NC*
Female	0.60	1	NC*				
Total	1.46	1	NC*				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	0.12	0	NC*	Male	0.14	0	NC*
Female	0.03	0	NC*	Female	0.11	0	NC*
Total	0.15	0	NC*	Total	0.25	0	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.03	0	NC*	Male	2.00	0	NC*
Female	0.02	0	NC*				
Total	0.05	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	0.19	0	NC*	Male	0.15	0	NC*
Female	0.09	0	NC*	Female	0.06	0	NC*
Total	0.27	0	NC*	Total	0.21	0	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.11	0	NC*	Male	0.03	0	NC*

Female	0.02	0	NC*
Total	0.13	0	NC*

#### Leukemia

Male	0.15	0	NC*
Female	0.08	0	NC*
Total	0.23	0	NC*

#### Liver and Intrahepatic Bile Ducts

Male	0.07	0	NC*
Female	0.02	0	NC*
Total	0.10	0	NC*

#### Lung and Bronchus

Male	1.04	0	NC*
Female	0.61	1	NC*
Total	1.66	1	NC*

#### Thyroid

Male	0.03	0	NC*
Female	0.07	0	NC*
Total	0.10	0	NC*

#### Uteri, Corpus and Uterus, NOS

Female	0.28	0	NC*
--------	------	---	-----

#### All Sites / Types

Male	6.55	2	NC*
Female	4.50	6	133
Total	11.05	8	72

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Heath

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>			
Male	0.59	1	NC*
Female	0.17	0	NC*
Total	0.76	1	NC*

#### **Brain and Other Central Nervous System**

Male	0.18	1	NC*
Female	0.12	0	NC*
Total	0.29	1	NC*

#### **Breast**

Male	0.03	0	NC*
Female	3.04	4	NC*
Total	3.07	4	NC*

#### **Cervix Uteri**

Female	0.17	0	NC*
--------	------	---	-----

#### **Colon / Rectum**

Male	1.46	1	NC*
Female	1.06	0	NC*
Total	2.52	1	NC*

#### **Esophagus**

Male	0.22	0	NC*
Female	0.05	0	NC*

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Melanoma of Skin</u></b>			
Male	0.40	1	NC*
Female	0.25	1	NC*
Total	0.65	2	NC*

#### **Multiple Myeloma**

Male	0.12	0	NC*
Female	0.08	0	NC*
Total	0.20	0	NC*

#### **Non-Hodgkin('s) Lymphoma**

Male	0.48	0	NC*
Female	0.33	1	NC*
Total	0.81	1	NC*

#### **Oral Cavity and Pharynx**

Male	0.39	0	NC*
Female	0.15	0	NC*
Total	0.54	0	NC*

#### **Ovary**

Female	0.35	0	NC*
--------	------	---	-----

#### **Pancreas**

Male	0.25	0	NC*
Female	0.20	0	NC*



Total	0.27	0	NC*
<b>Hodgkin's Disease (Hodgkin Lymphoma)</b>			
Male	0.08	0	NC*
Female	0.05	0	NC*
Total	0.14	0	NC*
<b>Kidney and Renal Pelvis</b>			
Male	0.35	1	NC*
Female	0.18	0	NC*
Total	0.53	1	NC*
<b>Larynx</b>			
Male	0.20	0	NC*
Female	0.04	0	NC*
Total	0.25	0	NC*
<b>Leukemia</b>			
Male	0.28	0	NC*
Female	0.18	0	NC*
Total	0.46	0	NC*
<b>Liver and Intrahepatic Bile Ducts</b>			
Male	0.14	0	NC*
Female	0.04	0	NC*
Total	0.18	0	NC*
<b>Lung and Bronchus</b>			
Male	1.84	1	NC*
Female	1.18	0	NC*
Total	3.02	1	NC*

Total	0.45	0	NC*
<b>Prostate</b>			
Male	3.67	3	NC*
<b>Stomach</b>			
Male	0.26	0	NC*
Female	0.12	0	NC*
Total	0.37	0	NC*
<b>Testis</b>			
Male	0.12	0	NC*
<b>Thyroid</b>			
Male	0.08	0	NC*
Female	0.17	1	NC*
Total	0.25	1	NC*
<b>Uteri, Corpus and Uterus, NOS</b>			
Female	0.59	0	NC*
<b>All Sites / Types</b>			
Male	11.91	9	76
Female	9.18	7	76
Total	21.09	16	76

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Hingham

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b>Bladder, Urinary</b>			
Male	14.69	19	129
Female	5.53	6	108
Total	20.22	25	124
<b>Brain and Other Central Nervous System</b>			
Male	4.43	1	NC*
Female	3.55	5	141
Total	7.98	6	75
<b>Breast</b>			
Male	0.71	2	NC*
Female	94.31	101	107
Total	95.02	103	108

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b>Melanoma of Skin</b>			
Male	9.98	15	150
Female	7.56	10	132
Total	17.53	25	143
<b>Multiple Myeloma</b>			
Male	2.95	2	NC*
Female	2.58	2	NC*
Total	5.53	4	NC*
<b>Non-Hodgkin('s) Lymphoma</b>			
Male	11.88	10	84
Female	10.64	10	94
Total	22.52	20	89

**Cervix Uteri**

Female	5.03	4	NC*
--------	------	---	-----

**Colon / Rectum**

Male	36.69	31	84
Female	34.50	35	101
Total	71.18	66	93

**Esophagus**

Male	5.51	6	109
Female	1.68	0	NC*
Total	7.19	6	83

**Hodgkin's Disease (Hodgkin Lymphoma)**

Male	2.05	1	NC*
Female	1.57	3	NC*
Total	3.62	4	NC*

**Kidney and Renal Pelvis**

Male	9.02	12	133
Female	5.58	5	90
Total	14.60	17	116

**Larynx**

Male	5.24	5	95
Female	1.34	0	NC*
Total	6.57	5	76

**Leukemia**

Male	6.91	4	NC*
Female	5.43	1	NC*
Total	12.34	5	41 #--

**Liver and Intrahepatic Bile Ducts**

Male	3.50	4	NC*
Female	1.41	2	NC*
Total	4.91	6	122

**Lung and Bronchus**

Male	47.82	31	65 #--
Female	38.41	25	65 #--
Total	86.23	56	65 ^--

**Oral Cavity and Pharynx**

Male	9.66	7	72
Female	4.60	3	NC*
Total	14.26	10	70

**Ovary**

Female	10.85	13	120
--------	-------	----	-----

**Pancreas**

Male	6.28	7	112
Female	6.41	7	109
Total	12.69	14	110

**Prostate**

Male	94.86	99	104
------	-------	----	-----

**Stomach**

Male	6.22	2	NC*
Female	3.71	3	NC*
Total	9.93	5	50

**Testis**

Male	2.90	3	NC*
------	------	---	-----

**Thyroid**

Male	1.94	2	NC*
Female	5.00	10	200
Total	6.94	12	173

**Uteri, Corpus and Uterus, NOS**

Female	18.57	16	86
--------	-------	----	----

**All Sites / Types**

Male	303.03	283	93
Female	288.51	279	97
Total	591.54	562	95

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

**Hinsdale**

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

<u>Bladder, Urinary</u>	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>	<u>Melanoma of Skin</u>	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
-------------------------	------------	------------	------------	-------------------------	------------	------------	------------

Male	1.48	1	NC*
Female	0.54	0	NC*
Total	2.02	1	NC*

#### **Brain and Other Central Nervous System**

Male	0.43	0	NC*
Female	0.33	0	NC*
Total	0.77	0	NC*

#### **Breast**

Male	0.07	0	NC*
Female	8.55	7	82
Total	8.62	7	81

#### **Cervix Uteri**

Female	0.48	2	NC*
--------	------	---	-----

#### **Colon / Rectum**

Male	3.67	5	136
Female	3.39	7	207
Total	7.06	12	170

#### **Esophagus**

Male	0.54	0	NC*
Female	0.16	0	NC*
Total	0.71	0	NC*

#### **Hodgkin's Disease (Hodgkin Lymphoma)**

Male	0.20	0	NC*
Female	0.16	0	NC*
Total	0.37	0	NC*

#### **Kidney and Renal Pelvis**

Male	0.88	1	NC*
Female	0.51	1	NC*
Total	1.39	2	NC*

#### **Larynx**

Male	0.51	0	NC*
Female	0.12	0	NC*
Total	0.63	0	NC*

#### **Leukemia**

Male	0.69	5	729 ~+
Female	0.52	1	NC*
Total	1.21	6	495 ~+

#### **Liver and Intrahepatic Bile Ducts**

Male	0.34	0	NC*
Female	0.13	0	NC*
Total	0.48	0	NC*

#### **Lung and Bronchus**

Male	4.66	2	NC*
Female	3.45	1	NC*
Total	8.11	3	NC*

Male	0.99	0	NC*
Female	0.72	0	NC*
Total	1.71	0	NC*

#### **Multiple Myeloma**

Male	0.29	0	NC*
Female	0.24	0	NC*
Total	0.53	0	NC*

#### **Non-Hodgkin('s) Lymphoma**

Male	1.19	1	NC*
Female	1.01	1	NC*
Total	2.20	2	NC*

#### **Oral Cavity and Pharynx**

Male	0.95	1	NC*
Female	0.42	0	NC*
Total	1.38	1	NC*

#### **Ovary**

Female	0.99	4	NC*
--------	------	---	-----

#### **Pancreas**

Male	0.63	0	NC*
Female	0.62	0	NC*
Total	1.25	0	NC*

#### **Prostate**

Male	9.20	6	65
------	------	---	----

#### **Stomach**

Male	0.63	0	NC*
Female	0.37	2	NC*
Total	1.00	2	NC*

#### **Testis**

Male	0.29	0	NC*
------	------	---	-----

#### **Thyroid**

Male	0.19	0	NC*
Female	0.49	0	NC*
Total	0.68	0	NC*

#### **Uteri, Corpus and Uterus, NOS**

Female	1.64	1	NC*
--------	------	---	-----

#### **All Sites / Types**

Male	29.84	24	80
Female	26.84	28	104
Total	56.68	52	92

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Holbrook

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	7.42	11	148	Male	4.93	1	NC*
Female	2.90	4	NC*	Female	3.92	1	NC*
Total	10.32	15	145	Total	8.85	2	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	2.22	2	NC*	Male	1.45	2	NC*
Female	1.87	0	NC*	Female	1.33	0	NC*
Total	4.09	2	NC*	Total	2.78	2	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.35	0	NC*	Male	5.95	10	168
Female	47.54	41	86	Female	5.62	5	89
Total	47.89	41	86	Total	11.57	15	130
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	2.68	0	NC*	Male	4.63	12	259 ~+
				Female	2.34	4	NC*
				Total	6.97	16	230 ~+
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	18.57	26	140	Female	5.54	7	126
Female	18.12	19	105				
Total	36.69	45	123				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	2.70	4	NC*	Male	3.13	2	NC*
Female	0.89	0	NC*	Female	3.39	5	148
Total	3.58	4	NC*	Total	6.52	7	107
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	1.10	1	NC*	Male	47.94	44	92
Female	0.90	1	NC*				
Total	2.00	2	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	4.39	3	NC*	Male	3.10	1	NC*
Female	2.88	1	NC*	Female	1.94	3	NC*
Total	7.27	4	NC*	Total	5.04	4	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	2.54	3	NC*	Male	1.67	1	NC*
Female	0.68	0	NC*				
Total	3.22	3	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	3.47	4	NC*	Male	0.98	0	NC*
Female	2.79	4	NC*	Female	2.71	0	NC*
Total	6.25	8	128	Total	3.69	0	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	1.72	1	NC*	Female	9.28	11	119
Female	0.74	2	NC*				

Total	2.46	3	NC*
<b><u>Lung and Bronchus</u></b>			
Male	24.14	39	162 ~+
Female	20.10	27	134
Total	44.24	66	149 ~+

#### **All Sites / Types**

Male	152.43	181	119 #+
Female	148.64	146	98
Total	301.07	327	109

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## **Holden**

**Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999**

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Bladder, Urinary</u></b>			
Male	11.48	4	NC*
Female	4.37	3	NC*
Total	15.85	7	44 #-

#### **Brain and Other Central Nervous System**

Male	3.31	3	NC*
Female	2.66	4	NC*
Total	5.97	7	117

#### **Breast**

Male	0.55	0	NC*
Female	70.02	56	80
Total	70.56	56	79

#### **Cervix Uteri**

Female	3.71	3	NC*
--------	------	---	-----

#### **Colon / Rectum**

Male	28.47	26	91
Female	27.38	26	95
Total	55.85	52	93

#### **Esophagus**

Male	4.20	1	NC*
Female	1.33	0	NC*
Total	5.53	1	NC*

#### **Hodgkin's Disease (Hodgkin Lymphoma)**

Male	1.49	1	NC*
Female	1.18	3	NC*
Total	2.68	4	NC*

#### **Kidney and Renal Pelvis**

Male	6.85	5	73
Female	4.21	3	NC*
Total	11.06	8	72

#### **Melanoma of Skin**

Male	7.55	4	NC*
Female	5.66	6	106
Total	13.21	10	76

#### **Multiple Myeloma**

Male	2.27	0	NC*
Female	1.98	2	NC*
Total	4.26	2	NC*

#### **Non-Hodgkin('s) Lymphoma**

Male	9.05	6	66
Female	8.19	6	73
Total	17.24	12	70

#### **Oral Cavity and Pharynx**

Male	7.30	2	NC*
Female	3.47	0	NC*
Total	10.77	2	NC*

#### **Ovary**

Female	8.06	10	124
--------	------	----	-----

#### **Pancreas**

Male	4.85	3	NC*
Female	5.03	6	119
Total	9.88	9	91

#### **Prostate**

Male	71.84	74	103
------	-------	----	-----

#### **Stomach**

Male	4.86	0	NC*
Female	2.96	1	NC*
Total	7.81	1	NC*

<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	3.95	1	NC*	Male	2.05	3	NC*
Female	0.98	1	NC*				
Total	4.93	2	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	5.31	2	NC*	Male	1.42	0	NC*
Female	4.18	6	144	Female	3.68	2	NC*
Total	9.49	8	84	Total	5.10	2	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	2.65	2	NC*				
Female	1.10	0	NC*	Female	13.70	11	80
Total	3.75	2	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	36.48	24	66 #-	Male	231.20	171	74 ^-
Female	28.98	16	55 #-	Female	218.72	177	81 ~-
Total	65.46	40	61 ^-	Total	449.92	348	77 ^-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Holland

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>		<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	1.31	1	NC*	Male	0.93	0	NC*
Female	0.41	1	NC*	Female	0.67	0	NC*
Total	1.72	2	NC*	Total	1.60	0	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.43	0	NC*	Male	0.26	0	NC*
Female	0.32	0	NC*	Female	0.20	0	NC*
Total	0.76	0	NC*	Total	0.46	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.06	0	NC*	Male	1.12	0	NC*
Female	7.79	3	NC*	Female	0.86	2	NC*
Total	7.85	3	NC*	Total	1.98	2	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	0.48	0	NC*	Male	0.90	0	NC*
				Female	0.37	0	NC*
				Total	1.27	0	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	3.28	5	153				
Female	2.58	4	NC*	Female	0.92	0	NC*
Total	5.86	9	154				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			

Male	0.50	0	NC*
Female	0.13	0	NC*
Total	0.62	0	NC*

#### **Hodgkin's Disease (Hodgkin Lymphoma)**

Male	0.22	0	NC*
Female	0.17	0	NC*
Total	0.39	0	NC*

#### **Kidney and Renal Pelvis**

Male	0.82	0	NC*
Female	0.45	0	NC*
Total	1.27	0	NC*

#### **Larynx**

Male	0.47	0	NC*
Female	0.11	0	NC*
Total	0.58	0	NC*

#### **Leukemia**

Male	0.65	1	NC*
Female	0.46	0	NC*
Total	1.12	1	NC*

#### **Liver and Intrahepatic Bile Ducts**

Male	0.32	0	NC*
Female	0.11	0	NC*
Total	0.43	0	NC*

#### **Lung and Bronchus**

Male	4.22	2	NC*
Female	3.00	4	NC*
Total	7.22	6	83

Male	0.57	0	NC*
Female	0.48	0	NC*
Total	1.05	0	NC*

#### **Prostate**

Male	8.37	7	84
------	------	---	----

#### **Stomach**

Male	0.57	0	NC*
Female	0.28	0	NC*
Total	0.85	0	NC*

#### **Testis**

Male	0.32	0	NC*
------	------	---	-----

#### **Thyroid**

Male	0.19	0	NC*
Female	0.51	0	NC*
Total	0.70	0	NC*

#### **Uteri, Corpus and Uterus, NOS**

Female	1.50	2	NC*
--------	------	---	-----

#### **All Sites / Types**

Male	27.36	17	62 #-
Female	23.39	16	68
Total	50.75	33	65 #-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (Obs / Exp) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## **Holliston**

**Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999**

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>			
Male	7.15	9	126
Female	2.56	1	NC*
Total	9.71	10	103

#### **Brain and Other Central Nervous System**

Male	2.82	1	NC*
Female	2.10	2	NC*
Total	4.92	3	NC*

#### **Breast**

Male	0.38	1	NC*
------	------	---	-----

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Melanoma of Skin</u></b>			
Male	5.88	4	NC*
Female	4.50	4	NC*
Total	10.38	8	77

#### **Multiple Myeloma**

Male	1.56	1	NC*
Female	1.29	0	NC*
Total	2.85	1	NC*

#### **Non-Hodgkin('s) Lymphoma**

Male	6.84	8	117
------	------	---	-----

Female	54.08	59	109
Total	54.46	60	110

#### Cervix Uteri

Female	3.27	1	NC*
--------	------	---	-----

#### Colon / Rectum

Male	18.37	17	93
Female	15.84	20	126
Total	34.22	37	108

#### Esophagus

Male	3.11	3	NC*
Female	0.77	0	NC*
Total	3.87	3	NC*

#### Hodgkin's Disease (Hodgkin Lymphoma)

Male	1.45	1	NC*
Female	1.05	0	NC*
Total	2.50	1	NC*

#### Kidney and Renal Pelvis

Male	5.19	3	NC*
Female	2.98	1	NC*
Total	8.17	4	NC*

#### Larynx

Male	3.06	3	NC*
Female	0.74	2	NC*
Total	3.81	5	131

#### Leukemia

Male	3.89	6	154
Female	2.95	3	NC*
Total	6.84	9	132

#### Liver and Intrahepatic Bile Ducts

Male	2.02	3	NC*
Female	0.68	0	NC*
Total	2.70	3	NC*

#### Lung and Bronchus

Male	25.33	13	51 #-
Female	19.81	18	91
Total	45.14	31	69 #-

Female	5.52	8	145
Total	12.36	16	129

#### Oral Cavity and Pharynx

Male	5.85	4	NC*
Female	2.49	1	NC*
Total	8.34	5	60

#### Ovary

Female	6.32	3	NC*
--------	------	---	-----

#### Pancreas

Male	3.31	2	NC*
Female	2.97	2	NC*
Total	6.28	4	NC*

#### Prostate

Male	51.76	51	99
------	-------	----	----

#### Stomach

Male	3.18	2	NC*
Female	1.71	1	NC*
Total	4.89	3	NC*

#### Testis

Male	2.22	2	NC*
------	------	---	-----

#### Thyroid

Male	1.33	1	NC*
Female	3.38	4	NC*
Total	4.71	5	106

#### Uteri, Corpus and Uterus, NOS

Female	10.53	7	66
--------	-------	---	----

#### All Sites / Types

Male	165.28	142	86
Female	155.60	146	94
Total	320.87	288	90

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Holyoke

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999



	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>			
Male	25.79	28	109
Female	11.46	12	105
Total	37.25	40	107
<b><u>Brain and Other Central Nervous System</u></b>			
Male	7.18	4	NC*
Female	6.72	7	104
Total	13.90	11	79
<b><u>Breast</u></b>			
Male	1.15	1	NC*
Female	160.83	146	91
Total	161.98	147	91
<b><u>Cervix Uteri</u></b>			
Female	8.92	17	191 #+
<b><u>Colon / Rectum</u></b>			
Male	63.20	79	125
Female	72.28	65	90
Total	135.48	144	106
<b><u>Esophagus</u></b>			
Male	8.50	11	129
Female	3.52	4	NC*
Total	12.02	15	125
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>			
Male	3.57	4	NC*
Female	3.29	4	NC*
Total	6.85	8	117
<b><u>Kidney and Renal Pelvis</u></b>			
Male	13.98	14	100
Female	10.18	9	88
Total	24.16	23	95
<b><u>Larynx</u></b>			
Male	7.76	10	129
Female	2.20	2	NC*
Total	9.96	12	120
<b><u>Leukemia</u></b>			
Male	12.07	14	116
Female	10.87	7	64
Total	22.94	21	92
<b><u>Liver and Intrahepatic Bile Ducts</u></b>			
Male	5.41	4	NC*
Female	2.84	2	NC*
Total	8.25	6	73
<b><u>Lung and Bronchus</u></b>			
Male	77.72	105	135 ~+
Female	69.52	61	88
Total	147.24	166	113

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Melanoma of Skin</u></b>			
Male	15.77	15	95
Female	13.70	12	88
Total	29.47	27	92
<b><u>Multiple Myeloma</u></b>			
Male	4.82	8	166
Female	4.88	5	102
Total	9.71	13	134
<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	19.64	15	76
Female	20.76	32	154 #+
Total	40.40	47	116
<b><u>Oral Cavity and Pharynx</u></b>			
Male	14.25	26	183 ~+
Female	8.32	11	132
Total	22.57	37	164 ~+
<b><u>Ovary</u></b>			
Female	18.82	23	122
<b><u>Pancreas</u></b>			
Male	10.39	13	125
Female	13.13	17	129
Total	23.52	30	128
<b><u>Prostate</u></b>			
Male	148.98	112	75 ~-
<b><u>Stomach</u></b>			
Male	10.64	14	132
Female	7.94	8	101
Total	18.58	22	118
<b><u>Testis</u></b>			
Male	5.20	3	NC*
<b><u>Thyroid</u></b>			
Male	2.92	0	NC*
Female	9.11	11	121
Total	12.04	11	91
<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Female	30.63	35	114
<b><u>All Sites / Types</u></b>			
Male	493.52	511	104
Female	531.39	536	101
Total	1024.91	1047	102

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Hopedale

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	4.05	4	NC*	Male	2.64	2	NC*
Female	1.44	1	NC*	Female	2.00	3	NC*
Total	5.50	5	91	Total	4.65	5	108
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	1.17	1	NC*	Male	0.78	1	NC*
Female	0.97	1	NC*	Female	0.66	1	NC*
Total	2.14	2	NC*	Total	1.44	2	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.19	0	NC*	Male	3.21	2	NC*
Female	23.85	25	105	Female	2.81	7	249
Total	24.04	25	104	Total	6.02	9	150
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	1.38	0	NC*	Male	2.49	0	NC*
				Female	1.17	2	NC*
				Total	3.67	2	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	10.05	6	60	Female	2.79	2	NC*
Female	9.02	8	89				
Total	19.07	14	73				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	1.45	2	NC*	Male	1.70	3	NC*
Female	0.44	0	NC*	Female	1.67	2	NC*
Total	1.89	2	NC*	Total	3.37	5	148
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.57	0	NC*	Male	25.00	29	116
Female	0.48	0	NC*				
Total	1.05	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	2.34	1	NC*	Male	1.72	1	NC*
Female	1.43	1	NC*	Female	0.97	0	NC*
Total	3.78	2	NC*	Total	2.69	1	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	1.35	2	NC*	Male	0.84	0	NC*
Female	0.33	0	NC*				
Total	1.68	2	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	1.88	1	NC*	Male	0.51	1	NC*
Female	1.45	0	NC*	Female	1.41	2	NC*
Total	3.33	1	NC*	Total	1.93	3	NC*

**Liver and Intrahepatic Bile Ducts**

Male	0.91	2	NC*
Female	0.37	0	NC*
Total	1.28	2	NC*

**Lung and Bronchus**

Male	12.69	5	39 #–
Female	9.83	9	92
Total	22.52	14	62

**Uteri, Corpus and Uterus, NOS**

Female	4.61	5	108
--------	------	---	-----

**All Sites / Types**

Male	81.01	67	83
Female	74.42	75	101
Total	155.43	142	91

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

– indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

**Hopkinton**

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	5.12	2	NC*	Male	4.26	8	188
Female	1.82	2	NC*	Female	3.24	5	154
Total	6.93	4	NC*	Total	7.51	13	173
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	2.07	5	241	Male	1.12	0	NC*
Female	1.57	2	NC*	Female	0.91	0	NC*
Total	3.64	7	192	Total	2.03	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.27	0	NC*	Male	4.98	3	NC*
Female	38.02	39	103	Female	3.97	6	151
Total	38.29	39	102	Total	8.95	9	101
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	2.37	3	NC*	Male	4.22	4	NC*
				Female	1.76	1	NC*
				Total	5.97	5	84
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	13.04	14	107	Female	4.49	5	111
Female	11.34	11	97				
Total	24.38	25	103				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	2.20	1	NC*	Male	2.35	3	NC*
Female	0.54	2	NC*	Female	2.10	4	NC*
Total	2.75	3	NC*	Total	4.45	7	157
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	1.08	0	NC*	Male	35.58	29	82
Female	0.81	1	NC*				
Total	1.89	1	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			

Male	3.74	3	NC*	Male	2.29	3	NC*
Female	2.10	1	NC*	Female	1.22	0	NC*
Total	5.85	4	NC*	Total	3.52	3	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	2.17	0	NC*	Male	1.66	1	NC*
Female	0.51	0	NC*				
Total	2.68	0	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	2.88	3	NC*	Male	0.97	3	NC*
Female	2.19	1	NC*	Female	2.50	3	NC*
Total	5.07	4	NC*	Total	3.47	6	173
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	1.44	0	NC*				
Female	0.49	1	NC*	Female	7.33	4	NC*
Total	1.93	1	NC*				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	17.67	16	91	Male	116.81	103	88
Female	13.84	18	130	Female	110.42	113	102
Total	31.52	34	108	Total	227.23	216	95

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Hubbardston

### Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>		<b><u>Exp</u></b>	<b><u>Obs</u></b>	<b><u>SIR</u></b>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	1.69	1	NC*	Male	1.34	1	NC*
Female	0.51	0	NC*	Female	0.94	1	NC*
Total	2.20	1	NC*	Total	2.28	2	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.65	0	NC*	Male	0.36	0	NC*
Female	0.45	0	NC*	Female	0.25	0	NC*
Total	1.10	0	NC*	Total	0.61	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.09	0	NC*	Male	1.58	1	NC*
Female	10.70	6	56	Female	1.13	2	NC*
Total	10.79	6	56	Total	2.71	3	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
				Male	1.32	1	NC*
Female	0.71	2	NC*	Female	0.49	0	NC*
				Total	1.82	1	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	4.30	3	NC*				

Female	3.22	3	NC*
Total	7.52	6	80

#### Esophagus

Male	0.71	0	NC*
Female	0.15	0	NC*
Total	0.86	0	NC*

#### Hodgkin's Disease (Hodgkin Lymphoma)

Male	0.33	0	NC*
Female	0.25	0	NC*
Total	0.58	0	NC*

#### Kidney and Renal Pelvis

Male	1.18	0	NC*
Female	0.59	1	NC*
Total	1.77	1	NC*

#### Larynx

Male	0.69	0	NC*
Female	0.14	0	NC*
Total	0.83	0	NC*

#### Leukemia

Male	0.92	2	NC*
Female	0.63	0	NC*
Total	1.54	2	NC*

#### Liver and Intrahepatic Bile Ducts

Male	0.46	0	NC*
Female	0.14	0	NC*
Total	0.60	0	NC*

#### Lung and Bronchus

Male	5.78	3	NC*
Female	3.84	2	NC*
Total	9.61	5	52

Female	1.28	3	NC*
--------	------	---	-----

#### Pancreas

Male	0.77	1	NC*
Female	0.59	1	NC*
Total	1.36	2	NC*

#### Prostate

Male	11.73	3	NC*
------	-------	---	-----

#### Stomach

Male	0.75	0	NC*
Female	0.35	1	NC*
Total	1.10	1	NC*

#### Testis

Male	0.49	1	NC*
------	------	---	-----

#### Thyroid

Male	0.30	1	NC*
Female	0.76	1	NC*
Total	1.05	2	NC*

#### Uteri, Corpus and Uterus, NOS

Female	2.03	0	NC*
--------	------	---	-----

#### All Sites / Types

Male	37.89	20	53 ~-
Female	31.26	23	74
Total	69.15	43	62 ~-

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Hudson

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<u>Bladder, Urinary</u>			
Male	9.93	11	111
Female	4.01	7	175
Total	13.94	18	129

#### Brain and Other Central Nervous System

Male	3.30	0	NC*
Female	2.65	3	NC*

#### Melanoma of Skin

Male	7.17	10	140
Female	5.62	1	NC*
Total	12.78	11	86

#### Multiple Myeloma

Male	1.99	1	NC*
Female	1.83	1	NC*

Total	5.95	3	NC*
<b><u>Breast</u></b>			
Male	0.48	1	NC*
Female	66.50	64	96
Total	66.98	65	97
<b><u>Cervix Uteri</u></b>			
Female	3.90	3	NC*
<b><u>Colon / Rectum</u></b>			
Male	24.89	25	100
Female	25.14	22	87
Total	50.03	47	94
<b><u>Esophagus</u></b>			
Male	3.73	2	NC*
Female	1.22	1	NC*
Total	4.95	3	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>			
Male	1.78	1	NC*
Female	1.34	3	NC*
Total	3.11	4	NC*
<b><u>Kidney and Renal Pelvis</u></b>			
Male	6.20	8	129
Female	3.97	1	NC*
Total	10.17	9	88
<b><u>Larynx</u></b>			
Male	3.55	7	197
Female	0.92	3	NC*
Total	4.47	10	224 #+
<b><u>Leukemia</u></b>			
Male	4.93	8	162
Female	3.95	7	177
Total	8.88	15	169
<b><u>Liver and Intrahepatic Bile Ducts</u></b>			
Male	2.41	2	NC*
Female	1.02	2	NC*
Total	3.43	4	NC*
<b><u>Lung and Bronchus</u></b>			
Male	32.17	52	162 ~+
Female	27.23	14	51 ~-
Total	59.39	66	111

Total	3.82	2	NC*
<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	8.58	6	70
Female	7.82	2	NC*
Total	16.40	8	49 #-
<b><u>Oral Cavity and Pharynx</u></b>			
Male	6.70	8	119
Female	3.26	3	NC*
Total	9.96	11	110
<b><u>Ovary</u></b>			
Female	7.79	3	NC*
<b><u>Pancreas</u></b>			
Male	4.27	4	NC*
Female	4.64	5	108
Total	8.92	9	101
<b><u>Prostate</u></b>			
Male	63.44	77	121
<b><u>Stomach</u></b>			
Male	4.26	3	NC*
Female	2.72	3	NC*
Total	6.98	6	86
<b><u>Testis</u></b>			
Male	2.84	3	NC*
<b><u>Thyroid</u></b>			
Male	1.54	2	NC*
Female	4.00	3	NC*
Total	5.54	5	90
<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Female	12.80	9	70
<b><u>All Sites / Types</u></b>			
Male	208.20	240	115 #+
Female	207.14	176	85 #-
Total	415.33	416	100

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

# Hull

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	6.45	9	139	Male	4.59	3	NC*
Female	2.35	3	NC*	Female	3.47	1	NC*
Total	8.80	12	136	Total	8.05	4	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	2.10	2	NC*	Male	1.28	0	NC*
Female	1.66	2	NC*	Female	1.10	2	NC*
Total	3.76	4	NC*	Total	2.39	2	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.31	0	NC*	Male	5.50	10	182
Female	41.20	43	104	Female	4.74	5	106
Total	41.52	43	104	Total	10.24	15	146
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	2.45	2	NC*	Male	4.29	9	210
				Female	1.99	1	NC*
				Total	6.28	10	159
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	16.15	20	124	Female	4.84	7	145
Female	14.71	19	129				
Total	30.86	39	126				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	2.41	3	NC*	Male	2.77	7	253 #+
Female	0.71	5	699 ~+	Female	2.74	2	NC*
Total	3.12	8	256 #+	Total	5.51	9	163
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	1.11	0	NC*	Male	41.06	43	105
Female	0.84	3	NC*				
Total	1.95	3	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	3.99	4	NC*	Male	2.76	3	NC*
Female	2.44	5	205	Female	1.57	2	NC*
Total	6.42	9	140	Total	4.34	5	115
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	2.28	4	NC*	Male	1.76	4	NC*
Female	0.58	0	NC*				
Total	2.86	4	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			
Male	3.17	1	NC*	Male	0.97	1	NC*
Female	2.39	2	NC*	Female	2.52	2	NC*
Total	5.56	3	NC*	Total	3.49	3	NC*
<b><u>Liver and Intrahepatic Bile Ducts</u></b>				<b><u>Uteri, Corpus and Uterus, NOS</u></b>			
Male	1.55	4	NC*	Female	7.99	7	88
Female	0.61	1	NC*				
Total	2.16	5	232				
<b><u>Lung and Bronchus</u></b>				<b><u>All Sites / Types</u></b>			
Male	20.82	29	139	Male	134.39	162	121 #+
Female	16.78	22	131	Female	126.43	148	117
Total	37.60	51	136 #+	Total	260.82	310	119 ~+

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels

## Huntington

Expected and Observed Case Counts, with Standardized Incidence Ratios, 1995 - 1999

	<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
<b><u>Bladder, Urinary</u></b>				<b><u>Melanoma of Skin</u></b>			
Male	1.43	3	NC*	Male	0.98	0	NC*
Female	0.44	0	NC*	Female	0.67	1	NC*
Total	1.87	3	NC*	Total	1.65	1	NC*
<b><u>Brain and Other Central Nervous System</u></b>				<b><u>Multiple Myeloma</u></b>			
Male	0.44	2	NC*	Male	0.29	0	NC*
Female	0.33	0	NC*	Female	0.21	0	NC*
Total	0.77	2	NC*	Total	0.49	0	NC*
<b><u>Breast</u></b>				<b><u>Non-Hodgkin('s) Lymphoma</u></b>			
Male	0.07	0	NC*	Male	1.18	0	NC*
Female	7.96	6	75	Female	0.89	0	NC*
Total	8.03	6	75	Total	2.07	0	NC*
<b><u>Cervix Uteri</u></b>				<b><u>Oral Cavity and Pharynx</u></b>			
Female	0.47	0	NC*	Male	0.93	1	NC*
				Female	0.38	0	NC*
				Total	1.31	1	NC*
<b><u>Colon / Rectum</u></b>				<b><u>Ovary</u></b>			
Male	3.54	0	NC*	Female	0.94	1	NC*
Female	2.75	1	NC*				
Total	6.29	1	NC*				
<b><u>Esophagus</u></b>				<b><u>Pancreas</u></b>			
Male	0.52	0	NC*	Male	0.60	0	NC*
Female	0.13	0	NC*	Female	0.51	0	NC*
Total	0.66	0	NC*	Total	1.11	0	NC*
<b><u>Hodgkin's Disease (Hodgkin Lymphoma)</u></b>				<b><u>Prostate</u></b>			
Male	0.22	0	NC*	Male	8.80	3	NC*
Female	0.16	0	NC*				
Total	0.38	0	NC*				
<b><u>Kidney and Renal Pelvis</u></b>				<b><u>Stomach</u></b>			
Male	0.87	1	NC*	Male	0.61	0	NC*
Female	0.46	1	NC*	Female	0.29	1	NC*
Total	1.34	2	NC*	Total	0.90	1	NC*
<b><u>Larynx</u></b>				<b><u>Testis</u></b>			
Male	0.50	2	NC*	Male	0.32	1	NC*
Female	0.11	0	NC*				
Total	0.60	2	NC*				
<b><u>Leukemia</u></b>				<b><u>Thyroid</u></b>			



Male	0.69	1	NC*
Female	0.47	0	NC*
Total	1.16	1	NC*

**Liver and Intrahepatic Bile Ducts**

Male	0.34	0	NC*
Female	0.11	0	NC*
Total	0.45	0	NC*

**Lung and Bronchus**

Male	4.53	2	NC*
Female	3.11	2	NC*
Total	7.64	4	NC*

Male	0.20	0	NC*
Female	0.49	2	NC*
Total	0.69	2	NC*

**Uteri, Corpus and Uterus, NOS**

Female	1.54	0	NC*
--------	------	---	-----

**All Sites / Types**

Male	29.01	19	65
Female	24.11	18	75
Total	53.12	37	70 #–

**Exp** = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer

**Obs** = observed case count

**SIR** = standardized incidence ratio [ (**Obs** / **Exp**) X 100 ]

\* = **SIR** and statistical significance not calculated when **Obs** < 5

+ indicates number of observed cases is statistically significantly higher than the expected number of cases

– indicates number of observed cases is statistically significantly lower than the expected number of cases

# indicates statistical significance at the  $p \leq 0.05$  level

~ indicates statistical significance at the  $p \leq 0.01$  level, as well as at the  $p \leq 0.05$  level

^ indicates statistical significance at the  $p \leq 0.001$  level, as well as at the  $p \leq 0.05$  and  $p \leq 0.01$  levels